Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL

Dec 11, 2019

By Simon Rule, MD

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

<<< View more from 2019 ASH Annual Meeting

Related Videos

Related Content

Real-World Data Highlight Underutilization of High-Dose Cytarabine/Transplant, Benefits of Maintenance Rituximab in MCL

January 24th 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Frontline Zanubrutinib Plus Rituximab Followed by Short-Course R-DHAOx Generates Preliminary Efficacy in MCL

January 15th 2023

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

December 31st 2022

Real-World Data Highlight Underutilization of High-Dose Cytarabine/Transplant, Benefits of Maintenance Rituximab in MCL

January 24th 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Frontline Zanubrutinib Plus Rituximab Followed by Short-Course R-DHAOx Generates Preliminary Efficacy in MCL

January 15th 2023

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

December 31st 2022

Real-World Data Highlight Underutilization of High-Dose Cytarabine/Transplant, Benefits of Maintenance Rituximab in MCL

January 24th 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Frontline Zanubrutinib Plus Rituximab Followed by Short-Course R-DHAOx Generates Preliminary Efficacy in MCL

January 15th 2023

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

December 31st 2022

Related Content

Real-World Data Highlight Underutilization of High-Dose Cytarabine/Transplant, Benefits of Maintenance Rituximab in MCL

January 24th 2023

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022

Frontline Zanubrutinib Plus Rituximab Followed by Short-Course R-DHAOx Generates Preliminary Efficacy in MCL

January 15th 2023

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

FDA Grants Orphan Drug Designation to LP-284 for Mantle Cell Lymphoma

January 9th 2023

For Staudt, a Keen Eye Sparks Opportunities to Dig Deeper

December 31st 2022

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.